39
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11635 |
IL-17A antagonist 1
|
IL Receptor | Immunology/Inflammation |
IL-17A antagonist 1 是一种 IL-17A 拮抗剂,可用于研究和白介素相关的炎症和免疫疾病。 | |||
T9448 |
IL-17A inhibitor 1
|
IL Receptor | Immunology/Inflammation |
IL-17A inhibitor 1 是 IL-17A 的抑制剂,在alphalisa assay 中的IC50为 <9.45 nM。IL-17A inhibitor 1抑制HT-29 细胞的 IC50 值为 9.3 nM。 | |||
T40355 | IL-17A modulator-2 | ||
IL-17A modulator-2, exhibits inhibitory properties towards IL-17A, with a pIC50 of 8.3. Its effectiveness lies in attenuating the biological effects associated with IL-17A activity. IL-17A modulator-2 finds utility in the study of diseases and disorders characterized by dysregulated IL-17A modulation, such as those involving immune dysfunction, autoimmune pathology, cancer, and neurodegenerative conditions. | |||
T40354 |
IL-17A modulator-1
|
||
IL-17A modulator-1 is an effective inhibitor of IL-17A activity, exhibiting a pIC 50 value of 8.2. This compound holds great promise for studying diseases and disorders that involve the modulation of IL-17A, such as immune-related diseases, autoimmune pathologies, cancer, and neurodegenerative disorders. | |||
T40116 | IL-17A inhibitor 2 | ||
IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis. | |||
T11636 |
IL-17A antagonist 3
|
IL Receptor | Immunology/Inflammation |
IL-17A antagonist 3 is an IL-17A antagonist. | |||
T14369 |
AZD-0284
|
ROR | Metabolism |
AZD-0284 是核受体 (RORγ) 的选择性反向激动剂。它对呼吸道疾病及斑块型寻常型银屑病具有潜在的应用价值。 | |||
T4050 |
GSK2981278
ROR gama modulator 1 |
ROR | Metabolism |
GSK2981278 (ROR gama modulator 1) 是 RORγ的选择性反向激动剂。它能够抑制 il17启动子的激活,并且干扰 RORγ-DNA 结合。 | |||
T6668 |
SGC-CBP30
|
Epigenetic Reader Domain; Histone Acetyltransferase | Chromatin/Epigenetic |
SGC-CBP30 是高选择性CBP/p300溴结构域的有效抑制剂,对CBP 和p300的Kd 值分别为 21 和 32 nM。它强烈减少 Th17 细胞中 IL-17A 的分泌,具有抗炎作用。 | |||
T72549 |
IL-17A modulator-3
|
||
IL-17Amodulator-3 是IL-17A 的调节剂。IL-17Amodulator-3 抑制 IL-17A/A,IC50值 <10 μM。IL-17Amodulator-3 可以用于炎症、癌症和自身免疫疾病的研究。 | |||
T76797 | Anti-Human IL-17A | ||
Anti-HumanIL-17A 是一种全人抗白细胞介素 17A 单克隆抗体。Anti-HumanIL-17A 可用于银屑病发病机制研究。 | |||
T38105 |
Ixekizumab
LY2439821 |
IL Receptor; Interleukin | Immunology/Inflammation |
Ixekizumab (LY2439821) 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A ,Kd 值<3 pM。Ixekizumab 科阻断 IL-17A 与 IL-17RA 的结合,但不与其他 IL-17 家族成员结合。Ixekizumab 用于治疗中重度斑块型银屑病、银屑病关节炎和牛皮癣。 | |||
T4403 |
AX-024 hydrochloride
AX-024 HCl |
IL Receptor; TNF; COX; IFNAR; Interleukin | Apoptosis; Immunology/Inflammation; Neuroscience |
AX-024 hydrochloride (AX-024 HCl) 是一种细胞因子释放抑制剂,可强烈抑制 IL-6、TNFα、IFN-γ、IL-10 和 IL-17A 的产生。它是口服可利用的 TCR-Nck 相互作用抑制剂,可选择性地抑制 TCR 触发的 T 细胞活化。它通过靶向 SH3结构域调节细胞信号传导,具有低毒、高效和高选择性的特点。 | |||
T9930 |
Secukinumab
|
IL Receptor | Immunology/Inflammation |
Secukinumab 是一种完全人源化的单克隆抗 IL-17A 抗体,是一个被美国食品和药物管理局批准用于治疗中度至重度斑块型银屑病的抗体。 | |||
T77677 |
12R-LOX-IN-2
|
Lipoxygenase | Metabolism |
12R-LOX-IN-2 是一种 12R-脂氧合酶 (12R-LOX) 的抑制剂。12R-LOX-IN-2 抑制咪喹莫特 (IMQ) 诱导银屑病角质形成细胞过度增殖,并抑制细胞集落形成。12R-LOX-IN-2 还降低 IMQ 诱导细胞中 Ki67 的蛋白水平和 IL-17A 的 mRNA 表达。12R-LOX-IN-2 可用于牛皮癣和其他皮肤相关炎症性疾病的研究。 | |||
T77030 | Gumokimab | ||
Gumokimab (AK 111) 是靶向IL-17A 的单克隆抗体,可用于银屑病、强直性脊柱炎的研究。Gumokimab 能够竞争性阻断人IL-17A 与IL-17R 的结合。 | |||
T71573 |
STK630921
|
||
STK630921 is a blocker of IL-17A binding to the IL-17A receptor (IL-17RA). | |||
T76953 | Xeligekimab | ||
Xeligekimab (GR 1501)为一种针对人白细胞介素17A (IL-17A) 的人源化单克隆抗体,可抑制促炎级联反应。 | |||
T76256 |
Erepdekinra
|
||
Erepdekinra 是一种白细胞介素-17A (IL-17A) 受体拮抗剂。 | |||
T77179 | Remtolumab | ||
Remtolumab (ABT-122) 是一种双变量域免疫球蛋白,可以中和肿瘤坏死因子α (TNFα) 和IL-17A。Remtolumab 显示出对 TNFα 和IL-17A 的双重抑制。Remtolumab 可用于类风湿关节炎 (RA) 研究。 | |||
T11308 |
FM26
|
ROR | Metabolism |
FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells. FM26 is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. | |||
T76901 | Afasevikumab | ||
Afasevikumab (RG 7624; RO 5553110; NI-1401) 是一种全人单克隆 IgG1κ 抗体,可中和 IL-17A 和 IL-17F。Afasevikumab 具有抗炎活性。 | |||
T25109 |
ARN-6039
ARN 6039,ARN6039 |
||
ARN-6039 is an orally available inverse agonist of RORγ for Autoimmune Neuroinflammatory Demyelinating Disease. The activity of ARN-6039 against RORγ was demonstrated in a RORγ-activated IL-17A Prom/LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 r | |||
T76823 | Perakizumab | ||
Perakizumab (RG4934)为针对IL-17A(Interleukin Related)的人源化IgG1κ单克隆抗体。适用于自身免疫性疾病(例如银屑病关节炎)的研究。 | |||
T79024 |
Androgen receptor-IN-5
|
Androgen Receptor | Endocrinology/Hormones |
Androgen Receptor-IN-5 为雄激素受体 (androgen receptor) 抑制剂,显示出有效的抗肿瘤活性。它亦能够抑制IL-17A、IL-17F及INF-γ的生成。 | |||
T63124 | RORγt modulator 4 | ||
RORγt modulator 4 是一种 RORγt 调节剂。RORγt modulator 4 能够调节源自小鼠脾脏的细胞中 IL-17A 产生的活性。 | |||
T76798 | Bimekizumab | ||
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) 是一种人源化单克隆抗体,可选择性中和 IL-17A 和 IL-17F。这两种细胞因子都能够促进成骨的人骨膜衍生细胞 (hPDC) 分化。因此,Bimekizumab 的应用,可以阻断炎症驱动的成骨分化。 | |||
T12750 |
ROR agonist-1
|
Others | Others |
ROR agonist-1 is a potent and orally bioavailable the retinoic acid receptor-related orphan receptor C2 (RORC2) inverse agonist(inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5). | |||
T62622 |
MRL-871
|
||
MRL-871 (compound 3) 是一种有效的异生维甲酸受体相关孤儿受体 γt (RORγt) 反向激动剂 (IC50: 264 nM)。MRL-871 表现出独特的异恶唑化学型,可有效减少 EL4 细胞中 IL-17a mRNA 的产生。 | |||
T10210 |
A-9758
|
ROR | Metabolism |
A-9758 is a RORγ ligand and a selective RORγt inverse agonist (IC50: 5 nM) and exhibits robust potency against IL-17A release. It is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 drive | |||
T70065 |
JNJ-61803534
|
||
JNJ-61803534 是一种有效的、具有口服活性 RORγt 反向激动剂,IC50为 9.6 nM。JNJ-61803534 具有抗炎活性。JNJ-61803534 在 Th17 分化条件下抑制人 CD4+ T 细胞产生 IL-17A。 | |||
T76885 | Sonelokimab | ||
Sonelokimab (ALX 0761; M 1095) 是三价纳米抗体,特异性结合人白介素(IL)-17A、IL-17F及人血清白蛋白VHH,由单价骆驼来源纳米抗体构成,展现于斑块型银屑病研究中的应用潜力。 | |||
T40043 |
RORγt Inverse agonist 10
|
||
RORγt Inverse agonist 10 is a highly potent and orally bioavailable compound that acts as an antagonist for the retinoic acid receptor-related orphan nuclear receptor gamma t (RORγt). With an IC50 of 51 nM, it effectively inhibits the activity of RORγt, a prominent transcription factor involved in the regulation of genes associated with the pathogenesis of psoriasis, including IL-17A, IL-22, and IL-23R. | |||
T76981 | Tibulizumab | ||
Tibulizumab (LY 3090106),一种四价双特异性单克隆抗体,针对 B 细胞激活因子 (BAFF) 与IL-17A,其 Kd 值分别为 60 pM 与 14 pM。该化合物适用于自身免疫性疾病的研究。 | |||
T83457 | 12R-LOX-IN-1 | ||
12R-LOX-IN-1(Compound 4a)是一种效能为IC50: 28.25 μM的12R-LOX抑制剂。该化合物能够有效抑制Imiquimod诱导的银屑病角质形成细胞的异常增殖和集落形成能力,同时减少活性氧、Ki67、IL-17A、TNF-α和IL-6的生成,适用于抗银屑病研究。 | |||
T36998 |
7β,27-dihydroxy Cholesterol
7β,27-DHC,7β,27-dihydroxy Cholesterol |
||
7β,27-dihydroxy Cholesterol is an oxysterol and agonist of retinoic acid receptor-related orphan receptor γ (RORγ) and RORγt. [1] It activates RORγ- or RORγt-dependent signaling with EC50 values of 691 and 1,045 nM, respectively, in reporter assays using HEK293T cells expressing the recombinant human receptors. 7β,27-dihydroxy Cholesterol is selective for RORγ and RORγt over a panel of eight additional nuclear receptors at 30 µM. It increases IL-17A production in Th17-polarized isolated hum... | |||
T61071 | AX-024 | ||
AX-024 is a novel chemical compound that acts as an orally available inhibitor of the TCR-Nck interaction. Its primary mechanism of action is the selective inhibition of T cell activation triggered by TCR stimulation. With an IC50 value of approximately 1 nM, AX-024 effectively modulates cell signaling by specifically targeting SH3 domains. Additionally, AX-024 demonstrates desirable characteristics such as low acute toxicity, high potency, and excellent selectivity. Notably, it exhibits strong ... | |||
T64300 | Vimirogant hydrochloride | ||
Vimirogant (VTP-43742) hydrochloride 是一种口服具有活力的、选择性的 RORγt 抑制剂 (IC50: 17 nM, Ki: 3.5 nM),选择性比 RORα 和 RORβ 大于 1000 倍。Vimirogant hydrochloride 能够抑制小鼠脾细胞的 Th17 分化和 IL-17A 分泌,其 IC50 值为 57 nM,且不影响 Th1,Th2 或 Treg 细胞的分化。Vimirogant hydrochloride 能够用于自身免疫性疾病的研究。 | |||
T76840 | Vunakizumab | ||
Vunakizumab (Anti-Human IL17A Recombinant Antibody) 是一种重组的人源化 IgGκ 单克隆抗体,可以靶向 IL-17A 并抑制其与 IL-17受体的相互作用。Vunakizumab 可用于研究银屑病关节炎、强直性脊柱炎、多发性硬化症和炎症性关节炎等自身免疫性疾病。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN7236 |
Cephalandole B
|
IL Receptor | Immunology/Inflammation |
cephalandole B 是一种从青黛中分离出两种吲哚生物碱,能明显地抑制了IL-17A 基因的表达,以剂量依赖的方式抑制了Jukat 细胞的IL-17A 荧光素酶报告。 | |||
TN6393 |
fulvotomentoside A
|
Others | Others |
fulvotomentoside A 可降低肠道中 IL-6 和 IL-17A 的过表达,并显着增加调节性 T 细胞特异性转录因子 Foxp3 的表达。这可能是Ful 改善肠道炎症的机制之一。 |